

Paper: PB.29.03.2018/16.iii

## NHS England – Board Paper

<b>Title:</b> Specialised Services Commissioning Committee (SSCC) Report
<b>Lead Director:</b> Noel Gordon – Non-Executive Director and Chair of the SSCC
<b>Purpose of Paper:</b> To update the Board on SSCC business
<b>The Board is invited to:</b> <ul style="list-style-type: none"><li>• note the work and key decisions of the SSCC</li></ul>

**Report to the Board from:** Specialised Services Commissioning Committee  
**Committee Chair:** Noel Gordon  
**Date of the Committee meeting:** 28 February 2018

## **Committee meetings**

1. This report covers the Committee meeting held on 28 February 2018.

## **Implementation**

### **Gender identity services – proposals for the new model of care**

2. The Committee received an overview of the current service model for gender identity services and proposed the development of a new model of care.
3. The following points were made in discussion:
  - The current service model is unable to accommodate increasing demand, and workforce is a major challenge in delivering these services. The proposed new model will address this by developing expertise beyond the current model of designated Gender Identity Clinics, taking account of views of key stakeholder groups. There is professional support for the proposals;
  - Whilst an integrated approach for patients of all ages is required, the model will need to recognise the particular needs of adolescents. It was proposed that the new model should be piloted in order to assess the approach; and
  - The Committee noted that development of the new model would not delay a planned national procurement of specialised gender identity services in 2018.
4. The Committee agreed to the following actions: develop the proposed new model of care, alongside other potential models, with a formal evaluation; engage relevant professional bodies and academics in the development of a training and accreditation process; formally engage Greater Manchester Health and Social Care Partnership as a potential pilot site; publish an independent analysis of consultation responses on these services.

### **Strategic priorities – specialised services**

5. The Committee received an overview of the proposed strategic priorities for specialised services for 2018/19 and 2019/20, which aim to: express specialised commissioning's contribution to the priorities set out in *Next Steps on the NHS Five Year Forward View*; present a clear basis for providing assurance and support to delivery across national and regional specialised commissioning teams; and support the development of the next Specialised Services Commissioning Intentions, to be published in Autumn 2018, and the planning round for 2019/20 and beyond.

### **Commercial development work on new medicines in the NICE pipeline**

6. The Committee received an overview of the processes and governance used by the Commercial Development Team when negotiating with pharmaceutical companies on prices and commercial terms for new high-cost drugs.

7. The following points were made in discussion:
- The processes that are now in place have led to an increase in the percentage of drugs on which the commercial team is negotiating; and
  - The action taken has significantly improved NHS England's capability in relation to pharmaceutical negotiations and this is a base on which to further build commercial capacity.

### **Incentives to encourage NHS Trusts to switch to biosimilar medicines**

8. The Committee considered proposals for how NHS England could incentivise NHS trusts to switch to biosimilar medicines and away from more expensive originator products.

### **Assurance**

9. The Committee received updates on:
- the December 2017 and January 2018 meetings of the Patient and Public Voice Assurance Group;
  - the 2017/18 financial planning position at month 9, the position on provider contracts; and the business approach to 2018/19 contracts and allocations;
  - the Specialised Commissioning Oversight Group meetings in December 2017 and January 2018;
  - the Health and Justice Oversight Group meeting in February 2018;
  - the Armed Forces Oversight Group meeting in February 2018;
  - The Cancer Drugs Fund Investment Group;
  - The pre-exposure prophylaxis (PrEP) trial – at the time of the meeting, 101 clinics had been opened, and over 4,755 participants enrolled;
  - Specialised Commissioning's contribution to support the delivery of Transforming Care for people with learning disabilities; and
  - The progress being made in delivering on Child and Adolescent Mental Health Services (CAMHS) Tier 4 bed provision.